Literature DB >> 15723339

MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21).

Tomoko Kozu1, Tomofusa Fukuyama, Tohru Yamami, Kiwamu Akagi, Yasuhiko Kaneko.   

Abstract

The AML1-MTG8 fusion gene is generated by chromosome translocation t(8;21), which is frequently observed in acute myeloid leukemia. The fusion gene produces a chimeric transcription factor that suppresses the expression of AML1-target genes via the MTG8 part of the chimeric protein, which is thought to be the primary cause of leukemia. The C-terminal region of MTG8 contains the MYND domain, represented by highly conserved zinc-finger-like protein motifs, and is known to interact with corepressor proteins. We found that, instead of the MYND domain, an alternative last exon of MTG8 encoding 27 amino acids in-frame is expressed naturally in human adult testis and in several leukemia cell lines. This type of alternative splicing also occurred in the AML1-MTG8 fusion gene at high levels in leukemia cell lines with t(8;21), as well as in blast cells of leukemia patients with t(8;21). The variant proteins of both MTG8 and AML1-MTG8 reduced transcriptional repressor activity in a mammalian two-hybrid assay. However, mixed expression of these variants with wild-type MTG8 recovered their repressor activity, suggesting that these variants also act as repressors in vivo where wild-type MTG8 and other family members exist in abundance. On the other hand, the MYND-less variants acquired a higher affinity for binding to MTG8 and formed a multimer, whereas the wild-type protein forms a dimer. Thus, expression of the MYND-less variants by the dysregulation of splicing machinery, which stimulates the oligomerization of fusion proteins in leukemia cells, may enhance malignant conversion of hematopoietic cells. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15723339     DOI: 10.1002/gcc.20165

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  11 in total

1.  Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells.

Authors:  Hai-Tong Fang; Bo Zhang; Xiao-Fen Pan; Li Gao; Tao Zhen; Hong-Xia Zhao; Liang Ma; Jun Xie; Zi Liu; Xian-Jun Yu; Xin Cheng; Ting-Ting Feng; Feng-Xiang Zhang; Yong Yang; Zhong-Guo Hu; Guo-Qing Sheng; Yong-Long Chen; Sai-Juan Chen; Zhu Chen; Guang-Biao Zhou
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-27       Impact factor: 11.205

2.  RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development.

Authors:  Russell C DeKelver; Benjamin Lewin; Stephanie Weng; Ming Yan; Joseph Biggs; Dong-Er Zhang
Journal:  Leuk Lymphoma       Date:  2013-07-25

3.  Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Roland B Walter; George S Laszlo; Todd A Alonzo; Robert B Gerbing; Shawn Levy; Matthew P Fitzgibbon; Chelsea J Gudgeon; Rhonda E Ries; Kimberly H Harrington; Susana C Raimondi; Betsy A Hirsch; Alan S Gamis; Martin W McIntosh; Soheil Meshinchi
Journal:  Am J Hematol       Date:  2013-06-20       Impact factor: 10.047

4.  Repression of the PDCD2 gene by BCL6 and the implications for the pathogenesis of human B and T cell lymphomas.

Authors:  Beverly W Baron; Nancy Zeleznik-Le; Miriam J Baron; Catherine Theisler; Dezheng Huo; Matthew D Krasowski; Michael J Thirman; Rebecca M Baron; Joseph M Baron
Journal:  Proc Natl Acad Sci U S A       Date:  2007-04-27       Impact factor: 11.205

Review 5.  Acute myeloid leukemia with the 8q22;21q22 translocation: secondary mutational events and alternative t(8;21) transcripts.

Authors:  Luke F Peterson; Anita Boyapati; Eun-Young Ahn; Joseph R Biggs; Akiko Joo Okumura; Miao-Chia Lo; Ming Yan; Dong-Er Zhang
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113

6.  Acute myeloid leukemia with the t(8;21) translocation: clinical consequences and biological implications.

Authors:  Håkon Reikvam; Kimberley Joanne Hatfield; Astrid Olsnes Kittang; Randi Hovland; Øystein Bruserud
Journal:  J Biomed Biotechnol       Date:  2011-05-03

Review 7.  The quiescent cellular state is Arf/p53-dependent and associated with H2AX downregulation and genome stability.

Authors:  Ken-Ichi Yoshioka; Yuko Atsumi; Hirokazu Fukuda; Mitsuko Masutani; Hirobumi Teraoka
Journal:  Int J Mol Sci       Date:  2012-05-24       Impact factor: 6.208

Review 8.  RUNX1-ETO: Attacking the Epigenome for Genomic Instable Leukemia.

Authors:  Emiel van der Kouwe; Philipp Bernhard Staber
Journal:  Int J Mol Sci       Date:  2019-01-16       Impact factor: 5.923

Review 9.  Fusion transcripts: Unexploited vulnerabilities in cancer?

Authors:  Carla Neckles; Soumya Sundara Rajan; Natasha J Caplen
Journal:  Wiley Interdiscip Rev RNA       Date:  2019-08-13       Impact factor: 9.957

10.  Cooperation between RUNX1-ETO9a and novel transcriptional partner KLF6 in upregulation of Alox5 in acute myeloid leukemia.

Authors:  Russell C DeKelver; Benjamin Lewin; Kentson Lam; Yukiko Komeno; Ming Yan; Chandler Rundle; Miao-Chia Lo; Dong-Er Zhang
Journal:  PLoS Genet       Date:  2013-10-10       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.